Asia-Pacific
A fresh wave of deals highlights why investors favour IP firms and why independent outfits may soon have to rethink their strategy
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Ranjna Mehta-Dutt, who moved to Chadha & Chadha after 25 years at Remfry & Sagar, says the firm plans to expand its life sciences practice through targeted recruitment and dedicated teams for bigger clients
Law firms across the world are seemingly united in their reluctance to give juniors a chance, which shouldn’t be the case
Sponsored
Sponsored
-
Sponsored by Tilleke & GibbinsLinh Thi Mai Nguyen and Chi Lan Dang of Tilleke & Gibbins outline the IP changes that will come into force in 2023, and share their opinion on the merits and drawbacks of each -
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law summarises the key points of the Korean Intellectual Property Office’s updated guidance regarding artificial intelligence patent filings as the intellectual property world adapts to a growing area
-
Sponsored by FB RiceJacqueline Warner and Marcus Caulfield of FB Rice explain the significance of common general knowledge (CGK) in the patentability of inventions in Australia and the evidentiary processes that are adopted as a result
-
Sponsored by ABE & PartnersTakanori Abe of ABE & Partners examines the Tokyo District Court and Intellectual Property High Court rulings on Ricoh’s claim that Ds Japan infringed its patent rights regarding toner cartridges for printers
-
Sponsored by Saint Island International Patent & Law OfficesFrank Liu of Saint Island International Patent & Law Offices describes the progress of a significant patent infringement case in Taiwan and the extended involvement of the Intellectual Property and Commercial Court
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees
